For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Congratulations to Lynn Dwernychuk for being honoured with the CCTG Award for Excellence in Clinical Trials Conduct, presented to her last weekend at the Annual Spring Meeting of Participants. Lynn was recognized by her peers as an individual who exemplifies excellence in clinical trial operations and compliance. She serves as the Director of Clinical Research at the Saskatchewan Cancer Agency and holds an Adjunct Professorship with the College of Graduate Studies and Research at the University of Saskatchewan.
The CCTG Pharmacy Network is actively seeking pharmacy representation for the following:
CCTG is delighted to recognize the early career of Dr. Jelena Lukovic who was presented with the CCTG Dr. Ralph Meyer Phase III Young Investigator Award this past weekend at the Spring Meeting of Participants in Toronto. This award is given to an outstanding young investigator who is working on a CCTG Phase III clinical trial.She is the Canadian PI for the international NEEDS trial evaluating definitive chemoradiotherapy for squamous cell esophageal cancer.
CCTG is pleased to recognize the BC Cancer–Kelowna IND240 Clinical Trials Team with the IND Team Award which was presented to the recipients this weekend at the CCTG Spring Meeting. The award is presented to Non-MD trial team members from member centres for their efforts and dedication to the success of clinical trials in the IND Program.
Dr. Arielle Elkrief, MD, FRCPC is a clinician–scientist (FRQS J1) and Associate Professor in the Department of Medicine, Division of Oncology at the Centre hospitalier de l’Université de Montréal (CHUM), where she also serves as Co-Director of the CHUM Microbiome Centre.
